Organogenesis Holdings Inc
NASDAQ:ORGO

Watchlist Manager
Organogenesis Holdings Inc Logo
Organogenesis Holdings Inc
NASDAQ:ORGO
Watchlist
Price: 3.04 USD -0.33%
Market Cap: 403m USD
Have any thoughts about
Organogenesis Holdings Inc?
Write Note

Organogenesis Holdings Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Organogenesis Holdings Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Organogenesis Holdings Inc
NASDAQ:ORGO
Accrued Liabilities
$36.9m
CAGR 3-Years
-4%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accrued Liabilities
$14.6B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accrued Liabilities
$3.2B
CAGR 3-Years
27%
CAGR 5-Years
22%
CAGR 10-Years
28%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accrued Liabilities
$2.5B
CAGR 3-Years
7%
CAGR 5-Years
25%
CAGR 10-Years
24%
No Stocks Found

Organogenesis Holdings Inc
Glance View

Market Cap
403m USD
Industry
Biotechnology

Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 950 full-time employees. The company went IPO on 2016-12-02. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.

ORGO Intrinsic Value
3.4 USD
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Organogenesis Holdings Inc's Accrued Liabilities?
Accrued Liabilities
36.9m USD

Based on the financial report for Sep 30, 2024, Organogenesis Holdings Inc's Accrued Liabilities amounts to 36.9m USD.

What is Organogenesis Holdings Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
12%

Over the last year, the Accrued Liabilities growth was -23%. The average annual Accrued Liabilities growth rates for Organogenesis Holdings Inc have been -4% over the past three years , 12% over the past five years .

Back to Top